<?xml version='1.0' encoding='utf-8'?>
<rss version="2.0">
	<channel>
		<title>OOIR Trends: Clinical Medicine (Pharmacology &amp; Pharmacy)</title>
		<description>Aktuelle Paper-Trends im Bereich Clinical Medicine (Pharmacology &amp; Pharmacy) von OOIR (mit Titel und Metadaten von Crossref)</description>
		<link>https://ooir.org</link>
		<language>en-us</language>
		<pubDate>Sun, 23 Nov 2025 01:17:59 GMT</pubDate>
		<lastBuildDate>Sun, 23 Nov 2025 01:17:59 GMT</lastBuildDate>
		<item>
			<title>Nanobodies: a new paradigm for brain disorder therapies</title>
			<link>https://doi.org/10.1016/j.tips.2025.10.004</link>
			<description>Feld: Clinical Medicine
Kategorie: Pharmacology &amp; Pharmacy
Score: 468
Autoren: Pierre-André Lafon, Laurent Prézeau, Jean-Philippe Pin, Philippe Rondard
Journal: Trends in Pharmacological Sciences
Veröffentlicht: 2025-11-01
DOI: 10.1016/j.tips.2025.10.004
ISSN: 0165-6147
Tag der Erhebung (OOIR): 2025-11-23</description>
			<guid isPermaLink="false">ooir-trend-10.1016/j.tips.2025.10.004-2025-11-23-1</guid>
			<pubDate>Sat, 01 Nov 2025 00:00:00 GMT</pubDate>
		</item>
		<item>
			<title>MCH11, a new monoacylglycerol lipase inhibitor, reduces ethanol consumption and motivation to drink in mice, with sex-dependent differences</title>
			<link>https://doi.org/10.1016/j.biopha.2025.118662</link>
			<description>Feld: Clinical Medicine
Kategorie: Pharmacology &amp; Pharmacy
Score: 152
Autoren: Abraham B. Torregrosa, María S. García-Gutiérrez, Daniela Navarro, Francisco Navarrete, Jorge Manzanares
Journal: Biomedicine &amp;amp; Pharmacotherapy
Veröffentlicht: 2025-11-01
DOI: 10.1016/j.biopha.2025.118662
ISSN: 0753-3322
Tag der Erhebung (OOIR): 2025-11-23</description>
			<guid isPermaLink="false">ooir-trend-10.1016/j.biopha.2025.118662-2025-11-23-2</guid>
			<pubDate>Sat, 01 Nov 2025 00:00:00 GMT</pubDate>
		</item>
		<item>
			<title>Mass balance, pharmacokinetics, metabolism, and excretion of radiolabeled acoziborole, a potential novel treatment for human African trypanosomiasis, following single microtracer oral dose to humans</title>
			<link>https://doi.org/10.1128/aac.00580-25</link>
			<description>Feld: Clinical Medicine
Kategorie: Pharmacology &amp; Pharmacy
Score: 142
Autoren: Jean-Yves Gillon, François Simon, Sharan Sidhu, Mathieu Louis, Delphine Launay, Valérie Wauthier, Marta Pelay-Gimeno, Lotte van Andel, Sabrina Loyau, Sandra Rembry, Estelle Weinling, Antoine Tarral
Journal: Antimicrobial Agents and Chemotherapy
Veröffentlicht: 2025-11-05
Abstract: ABSTRACT
                  
                    
                    
                      Acoziborole is an oxaborole 6-carboxamide active against
                      Trypanosoma brucei gambiense
                      and
                      rhodesiense
                      , the parasites responsible for human African trypanosomiasis. This open-label, phase I study in six healthy male participants evaluated the mass balance, pharmacokinetics, metabolism pathways, and excretion of a single oral 960 mg dose of [
                      14
                      C]-acoziborole. Blood, plasma, and feces were collected for 120 days and urine for 16 days. The excretion balance and systemic exposure of total circulating radioactivity were determined using accelerator mass spectrometry. Metabolism profiling was performed in pools of plasma, urine, and feces. Liquid chromatography coupled with tandem mass spectrometry quantified acoziborole and its metabolite SCYX-3109 in plasma and urine. By Day 60, 87.3% of the total radioactivity had been recovered (10.9% and 74.2% of the total dose in urine and in feces, respectively), with an excretion increment of &amp;lt;1% between Days 59 and 61. Mean ratios of total radioactivity indicated an equivalent distribution between blood cells and plasma. The concentration-time profiles of total radioactivity and acoziborole in plasma were similar. In plasma, acoziborole accounted for 95.1%, an oxidized form of acoziborole for 2.3% of the total radioactivity, while SCYX-3109 was not detected. Seven metabolites (oxidative deboronation, glucuronidation, and mono-oxidation) were detected in urine with individual abundances relative to the dose of 0.1–2.1%; unchanged acoziborole accounted for 0.6%. In feces, acoziborole, SCYX-3109, and two other oxidized or deboronated forms of acoziborole represented 33.6%, 12.3%, and 2.3% of the dose, respectively. Acoziborole showed good absorption, limited metabolism, minimal urinary elimination, and predominant but slow biliary-fecal elimination.
                    
                  
DOI: 10.1128/aac.00580-25
ISSN: 0066-4804
Tag der Erhebung (OOIR): 2025-11-23</description>
			<guid isPermaLink="false">ooir-trend-10.1128/aac.00580-25-2025-11-23-3</guid>
			<pubDate>Wed, 05 Nov 2025 00:00:00 GMT</pubDate>
		</item>
		<item>
			<title>The continued impact of COVID-19 during the Omicron era on immunocompromised individuals in Japan</title>
			<link>https://doi.org/10.1016/j.jiac.2025.102840</link>
			<description>Feld: Clinical Medicine
Kategorie: Pharmacology &amp; Pharmacy
Score: 109
Autoren: Toshibumi Taniguchi, Mitsuru Hoshino, Ryotaro Ide, Tomoyuki Homma, Keiji Sugiyama, Shinichi Kanazu, Atsushi Maruyama, Kazuhiro Tateda
Journal: Journal of Infection and Chemotherapy
Veröffentlicht: 2025-12-01
DOI: 10.1016/j.jiac.2025.102840
ISSN: 1341-321X
Tag der Erhebung (OOIR): 2025-11-23</description>
			<guid isPermaLink="false">ooir-trend-10.1016/j.jiac.2025.102840-2025-11-23-4</guid>
			<pubDate>Mon, 01 Dec 2025 00:00:00 GMT</pubDate>
		</item>
		<item>
			<title>LSD microdosing in major depressive disorder: results from an open-label trial</title>
			<link>https://doi.org/10.1016/j.neuropharm.2025.110762</link>
			<description>Feld: Clinical Medicine
Kategorie: Pharmacology &amp; Pharmacy
Score: 103
Autoren: Dimitri Daldegan-Bueno, Carina Joy Donegan, Rachael Sumner, Anna Forsyth, William Evans, Malak Alshakhouri, Lisa Reynolds, Rhys Ponton, Todd Smith, Partha Roop, Nicholas Hoeh, Nathan Allen, Frederick Sundram, David Menkes, Suresh Muthukumaraswamy
Journal: Neuropharmacology
Veröffentlicht: 2026-02-01
DOI: 10.1016/j.neuropharm.2025.110762
ISSN: 0028-3908
Tag der Erhebung (OOIR): 2025-11-23</description>
			<guid isPermaLink="false">ooir-trend-10.1016/j.neuropharm.2025.110762-2025-11-23-5</guid>
			<pubDate>Sun, 01 Feb 2026 00:00:00 GMT</pubDate>
		</item>
	</channel>
</rss>